Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.

Conclusion: Despite their extensive use and costs, questions around optimal use of BMAs still exist. Practice varies according to patient insurance coverage. However, most physicians are de-escalating BMAs. There is interest amongst clinicians in performing trials of de-escalation, especially after 2 years of treatment. PMID: 33294318 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/33294318?dopt=Abstract

Source: Pain Physician - December 11, 2020 Category: Anesthesiology Authors: AlZahrani M, Clemons M, Vandermeer L, Sienkiewicz M, Awan AA, Hutton B, Pond GR, Ng TL Tags: J Bone Oncol Source Type: research